EN
Patient-first cell therapy innovation
 
2024
  • 0
Aberrant cytoplasmic expression of UHRF1 restrains the MHC-I-mediated anti-tumor immune response
. 2024 Oct 3;15:8569. doi: 10.1038/s41467-024-52902-5
Tan L, Yin T, Xiang H, Wang L, Mudgal P, Chen J, Ding Y, Wang G, Lim BJW, Huang Y, Huang D, Liang Y, Alexander PB, Xiang K, Wang E, Yan C, Ma Z, Tan M, Li QJ, Wang XF.

Breaking NGF-TrkA immunosuppression in melanoma sensitizes immunotherapy for durable memory T cell protection
. Author manuscript; available in PMC: 2025 Feb 1.
Published in final edited form as: Nat Immunol. 2024 Jan 9;25(2):268–281. doi: 10.1038/s41590-023-01723-7
Yin T, Wang G, Wang L, Mudgal P, Wang E, Pan CC, Alexander PB, Wu H, Cao C, Liang Y, Tan L, Huang D, Chong M, Chen R, Lim BJW, Xiang K, Xue W, Wan L, Hu H, Loh YH, Wang XF, Li QJ.


EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion

. 2024 Jun 17;12(6):e008375. doi: 10.1136/jitc-2023-008375
Chen Y, Ouyang D, Wang Y, Pan Q, Zhao J, Chen H, Yang X, Tang Y, Wang Q, Li Y, He J, You JQ, Li Y, Xu C, Ren Y, Xie S, Li S, Lian J, Weng D, Xiang T, Xia JC.

The role of circadian clock in regulating cell functions: implications for diseases

. 2024 Mar 11;5(3):e504. doi: 10.1002/mco2.504
Lin Y, He L, Cai Y, Wang X, Wang S, Li F.


Development of a Novel Pyroptosis-Associated lncRNA Biomarker Signature in Lung Adenocarcinoma


Wang P, Wang Z, Lin Y, Castellano L, Stebbing J, Zhu L, Peng L.
04.18
2025
Source:天科雅
Keysword:
Related Reading

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer
About TCRCure
Research and Development
Product and Cinical trial
News and Media
Recruitment

Copyright © 2019 TCR CURE Biopharma Technology Co., Ltd Powered by vancheer